

Press release

LEUKOCARE signs cooperation agreement with Sterigenics

Leukocare also closed a financing of EUR 1.6 M (\$2.2M)

Munich, Germany, 17.11.2010

LEUKOCARE AG, a privately-owned company developing innovative life science technologies, today announced the signing of a cooperation agreement with Sterigenics, a global leader for sterilization services. As part of this cooperation, LEUKOCARE plans to use their Stabilizing and Protecting Solutions (SPS) technology together with Sterigenics' irradiation expertise in order to establish new sterilization procedures for biotherapeutics, such as therapeutic antibodies. The project will aim to significantly improve the sterility and security for patients receiving biotherapeutics, as well as simplifying production processes and cost reductions.

"LEUKOCARE's unique technologies make the company a significant and exciting enterprise with a vast potential for success," commented Dirk Beelen, Vice President EMEAA Sales, Marketing and Business Development of Sterigenics. "We look forward to combining our expertise in irradiation with LEUKOCARE's SPS technology in order to create new sterilization procedures for biologics, in particular, therapeutic antibodies."

"We are delighted to start this project with Sterigenics, the international industry leaders for sterilization technology, as this will help us to establish a novel, state of the art method for processing biopharmaceuticals", stated Michael Scholl, CEO of LEUKOCARE. "Sterigenics is the ideal partner to further develop the stabilization of biologics during sterilization using our SPS technology."

At the same time as this collaboration, LEUKOCARE also announced the closing of a EUR 1.6 Million financing. LEUKOCARE's existing group of private investors as well as the German state-owned bank KfW, which has been a shareholder in LEUKOCARE since 2006, participated in this capital

increase. The investment strengthens LEUKOCARE's financial position and paves the way for the next strategic steps in its development.

About LEUKOCARE

LEUKOCARE is a leading solution provider of biofunctional surfaces for medical devices and stabilized proteins resistant to sterilization processes. As a product-focused, clinical-stage biotechnology company, LEUKOCARE uses its proprietary stabilizing postcoating technology to couple, protect and elute biofunctional molecules. LEUKOCARE can functionalize a wide variety of surfaces including implant surfaces, wound dressings, patches, stents, catheters, columns for ex-vivo blood treatment and others. LEUKOCARE leverages its comprehensive biofunctional coating expertise in product-focused industry partnerships. The company also offers its know-how in biofunctional coatings and product development to interested parties on a flexible basis, ranging from service-based collaborations to co-development partnerships. LEUKOCARE is a privately-owned biotechnology company founded in 2003 and headquartered in Martinsried near Munich, Germany.

For further information, please visit www.LEUKOCARE.com.

About Sterigenics

Sterigenics International Inc. is a portfolio company of Silverfleet Capital and PPM America Capital Partners. Headquartered in the Chicago suburb of Oak Brook, IL, Sterigenics International is the only company in the world to offer technology in all leading sterilization modalities, including: gamma, ethylene oxide, electron beam and X-ray. The company has more than 1,300 employees and operates 38 service centres in North America, Europe and Asia.

For further information, please visit www.sterigenics.com.

Notes for editors:

Many biologics are prone to chemical and physical degradation as well as destabilization or unfolding in response to temperature, radiation, and hydrolysis during production, sterilization and storage. Thus shelf life and sterilization are key bottlenecks in the design strategies and market success of new products. LEUKOCARE's Stabilizing and Protecting Solutions (SPS) combine the stabilizing and protecting properties required for shelf life extension and radiation protection in one single product.

For further information please contact:

Julian Hergenröther

Business Development

Phone: +49 (0)89 780 16 65 – 13

Fax: +49 (0)89 780 16 65 – 11

Email: julian.hergenroether@leukocare.com